United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Biotecnologia

Dr. Leigh  Peterson

Executive Vice President of Product Development & Xenotransplantation

Mr. Dewey  Steadman C.F.A.

Head of Investor Relations

Mr. Gil  Golden

Senior Vice President & Chief Medical Officer

Mr. Michael I. Benkowitz

President & Chief Operating Officer

Ms. Holly  Hobson

Associate Vice President of Human Resources

Kevin T. Gray

Senior Vice President of Strategic Operations & Logistics

Mr. Patrick  Poisson

Executive Vice President of Technical Operations

Mr. Paul A. Mahon J.D.

Executive Vice President, General Counsel & Corporate Secretary

Mr. James C. Edgemond

Chief Financial Officer & Treasurer

Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.

Founder, Chairman & Chief Executive Officer

Nome	Capitalizzazione di mercato
Maravai LifeSciences Holdings, Inc.	0M
Comera Life Sciences Holdings, Inc.	0M
CytoTools AG	0M
Hofseth BioCare ASA	0M
Purple Biotech Ltd.	0M
Starpharma Holdings Limited	0M

United Therapeutics Corporation

United Therapeutics Corporation Elenco dei concorrenti

Principali concorrenti